Abbott Laboratories Inc.’s blockbuster arthritis drug Humira (adalimumab) demonstrated an improvement in two new subsets of spondyloarthritis patients for which the drug is not currently indicated in Phase III studies presented at the European League Against Rheumatism (EULAR) Congress in Berlin June 6.
Data from two studies showed that Humira provided a benefit to patients with active peripheral spondyloarthritis (PSpA) who have not...